Psyence Biomedical Ltd
PBM2.740USD
-0.260-8.67%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
61.38KMarket Cap
LossP/E TTM
More Details of Psyence Biomedical Ltd Company
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Psyence Biomedical Ltd Info
Ticker SymbolPBM
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
CEODr. Neil Maresky
Number of employees12
Security typeOrdinary Share
Fiscal year-endDec 10
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Ticker SymbolPBM
IPO dateDec 10, 2021
CEODr. Neil Maresky
Company Executives of Psyence Biomedical Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Parallel Advisors, LLC
38.56%
Sabby Management, LLC
2.85%
White Lion Capital LLC
1.76%
AdvisorShares Investments, LLC
0.62%
BofA Global Research (US)
0.47%
Other
55.74%
Shareholders
Shareholders
Proportion
Parallel Advisors, LLC
38.56%
Sabby Management, LLC
2.85%
White Lion Capital LLC
1.76%
AdvisorShares Investments, LLC
0.62%
BofA Global Research (US)
0.47%
Other
55.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.53%
Investment Advisor/Hedge Fund
2.85%
Venture Capital
1.83%
Corporation
0.48%
Research Firm
0.47%
Other
54.83%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
38
318.71K
44.69%
+173.11K
2025Q2
45
357.80K
50.17%
+181.11K
2025Q1
45
167.96K
26.60%
+69.68K
2024Q4
82
948.20K
24.27%
+587.08K
2024Q3
88
169.92K
15.90%
-186.51K
2024Q2
92
159.62K
36.84%
-203.47K
2024Q1
96
157.41K
35.61%
-211.56K
2023Q4
88
18.95K
16.18%
-253.66K
2023Q3
87
16.58K
55.18%
-252.44K
2023Q2
86
17.96K
50.97%
-264.02K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Parallel Advisors, LLC
275.00K
38.56%
+275.00K
--
Jun 30, 2025
Sabby Management, LLC
20.33K
2.85%
-11.88K
-36.89%
Jun 30, 2025
White Lion Capital LLC
12.55K
1.76%
+12.55K
--
Dec 04, 2024
AdvisorShares Investments, LLC
4.45K
0.62%
-1.00
-0.02%
Jun 30, 2025
BofA Global Research (US)
3.34K
0.47%
+3.34K
--
Jun 30, 2025
Launchpad Ignition Holdings LLC
2.00K
0.28%
+2.00K
--
Mar 31, 2024
UBS Financial Services, Inc.
1.96K
0.27%
-2.25K
-53.55%
Jun 30, 2025
Tabula Rasa Ltd
1.45K
0.2%
-728.00
-33.47%
Mar 31, 2024
Stonehage Fleming Financial Services Holdings, Ltd.
561.00
0.08%
-1.00
-0.18%
Jun 30, 2025
Launchpad Capital Management Company, LLC
529.00
0.07%
+529.00
--
Mar 31, 2024
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
AdvisorShares Psychedelics ETF
0.13%
AdvisorShares Psychedelics ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Date
Type
Ratio
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
